What is it about?

The RAPID trial showed definitive support for the use of AAT replacement therapy for those with Alpha 1 antitrypsin deficiency (AATD). The result showed the treatment slowed the decline of total lung capacity and extending life spans for patients with AATD. It also highlights the use of CT scans as a sensitive and specific measure of disease progression.

Featured Image

Why is it important?

There is much to learn about Alpha 1 antitrypsin deficiency and much to share. This paper provides an expert review of the status of treatments, guidelines, and what's to come.

Perspectives

Raising awareness of the effectiveness of treatment can help to inspire increases in screening for Alpha 1 antitrypsin deficiency. This can further support new guidelines for personalized treatment approaches with pharmacological and lifestyle interventions.

Professor Kenneth R Chapman
University of Toronto

Read the Original

This page is a summary of: Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications, International Journal of Chronic Obstructive Pulmonary Disease, January 2018, Dove Medical Press, DOI: 10.2147/copd.s149429.
You can read the full text:

Read
Open access logo

Resources

Contributors

The following have contributed to this page